Aniracetam

Tier 3 — weak evidence · Nootropic · Anxiety · AMPA modulation

A fat-soluble racetam nootropic that modulates AMPA glutamate receptors and enhances cholinergic transmission. Approved as a prescription drug in some European countries for cognitive impairment. Small trials suggest anxiolytic effects mediated through dopamine and serotonin modulation. Not approved in the US. Short half-life of 1–2 hours requires multiple daily doses. Limited modern clinical data.

Dose: 750–1,500 mg/day in 2–3 divided doses; take with fat for absorption; pair with a choline source